CervoMed Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CervoMed Inc. (CRVO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $9.87 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-03-24
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $10.90, a 928.30% increase year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $1.06, a 194.44% increase year-over-year.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.36.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $9.87, a 77.90% decline from fiscal 2021.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $44.66, a 6878.13% increase from fiscal 2020.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $0.64, a 70.37% decline from fiscal 2019.
- CervoMed Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $2.16, a 82.90% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $9.87 10-K · filed 2023-03-24 | ||||
| 2022-09-30 | $9.87 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $10.35 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $10.90 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $44.66 10-K · filed 2023-03-24 | $0.89 10-K · filed 2022-03-18 | |||
| 2021-09-30 | $0.87 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $1.05 10-Q · filed 2021-08-11 | ||||
| 2021-03-31 | $1.06 10-Q · filed 2021-05-07 | ||||
| 2020-12-31 | $0.64 10-K · filed 2022-03-18 | ||||
| 2020-09-30 | $0.62 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $0.46 10-Q · filed 2020-08-07 | ||||
| 2020-03-31 | $0.36 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $2.16 10-K · filed 2021-03-17 | ||||
| 2018-12-31 | $12.63 10-K · filed 2020-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |